Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status: The strong heart study

Diabetes Care

Volumn 40, Issue 4, 2017, Pages 529-537

  Lee, Jennifer S ^a,b   Chang, Po Yin ^a   Zhang, Ying ^c   Kizer, Jorge R ^d   Best, Lyle G ^e   Howard, Barbara V ^f  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e MISSOURI BREAKS INDUSTRIES RESEARCH INC   (United States)

^f MEDSTAR HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL;

ADULT; AGE; AGED; AMERICAN INDIAN; ARTICLE; BODY MASS; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PROSPECTIVE STUDY; SEX; SMOKING; BLOOD; COMPLICATION; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STROKE;

AGED; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; STROKE; TRIGLYCERIDES;

EID: 85019616311     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-1958     Document Type: Article

References (40)

1. Di Angelantonio E, Sarwar N, Perry P, et al.; Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000
2. Tanne D, Koren-Morag N, Graff E, Goldbourt U. Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor. Circulation 2001;104:2892-2897
3. O'Donnell MJ, Xavier D, Liu L, et al.; INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010;376:112-123
4. Carey VJ, Bishop L, Laranjo N, Harshfield BJ, Kwiat C, Sacks FM. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol 2010; 106:757-763
5. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 2005;46:1225-1228
6. Leiter LA, Lundman P, da Silva PM, Drexel H, Junger C, Gitt AK; DYSIS investigators. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med 2011;28:1343-1351
7. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med 2001;161:361-366
8. Abdel-Maksoud MF, Eckel RH, Hamman RF, Hokanson JE. Risk of coronary heart disease is associated with triglycerides and high-density lipoprotein cholesterol in women and nonhigh- density lipoprotein cholesterol in men. J Clin Lipidol 2012;6:374-381
9. Rana JS, VisserME, Arsenault BJ, et al.Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Int J Cardiol 2010;143: 399-404
10. Andersson C, Lyass A, Vasan RS, Massaro JM, D'Agostino RB Sr., Robins SJ. Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study. Am Heart J 2014; 168:878-883.e1
11. Sparks JD, Sparks CE, Adeli K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2012;32:2104-2112
12. Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia 2015; 58:886-899
13. Soran H, Schofield JD, Adam S, Durrington PN. Diabetic dyslipidaemia. Curr Opin Lipidol 2016;27:313-322
14. Adiels M, Olofsson SO, Taskinen MR, Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:1225-1236
15. Ginsberg HN, Elam MB, Lovato LC, et al.; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574
16. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA 2016;315:2284-2291
17. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA 2015;314:1021-1029
18. Rana JS, Liu JY, Moffet HH, et al. Metabolic dyslipidemia and risk of coronary heart disease in 28, 318 adults with diabetes mellitus and lowdensity lipoprotein cholesterol, 100 mg/dl. Am J Cardiol 2015;116:1700-1704
19. Howard BV, Lee ET, Cowan LD, et al. Rising tide of cardiovascular disease inAmerican Indians. The Strong Heart Study. Circulation 1999;99: 2389-2395
20. Lee ET, Welty TK, Fabsitz R, et al. The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol 1990;132:1141-1155
21. Howard BV, Welty TK, Fabsitz RR, et al. Risk factors for coronary heart disease in diabetic and nondiabetic Native Americans. The Strong Heart Study. Diabetes 1992;41(Suppl. 2): 4-11
22. Robbins DC, Welty TK, Wang WY, Lee ET, Howard BV. Plasma lipids and lipoprotein concentrations among American Indians: comparison with the US population. Curr Opin Lipidol 1996;7:188-195
23. Department of Health, Education, andWelfare. Lipid Research Clinics Program: Manual of Laboratory Operations. Washington, DC, U.S. Govt. Printing Office, 1994 (DHEW publ. no. 75-628)
24. Morgan CR, Lazarow A. Immunoassay of insulin using a two-antibody system. Proc Soc Exp Biol Med 1962;110:29-32
25. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957;17:237-246 [in German]
26. Chasson AL, Grady HJ, Stanley MA. Determination of creatinine by means of automatic chemical analysis. Tech Bull RegistMed Technol 1960;30:207-212
27. Xu J, Lee ET, Peterson LE, et al. Differences in risk factors for coronary heart disease among diabetic and nondiabetic individuals froma population with high rates of diabetes: the Strong Heart Study. J Clin Endocrinol Metab 2012;97: 3766-3774
28. Shara NM, Wang H, Mete M, et al. Estimated GFR and incident cardiovascular disease events in American Indians: the Strong Heart Study. Am J Kidney Dis 2012;60:795-803
29. Levey AS, Stevens LA, Schmid CH, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-612
30. Fretts AM, Howard BV, Kriska AM, et al. Physical activity and incident diabetes in American Indians: the Strong Heart Study. Am J Epidemiol 2009;170:632-639
31. Kriska AM, Knowler WC, LaPorte RE, et al. Development of questionnaire to examine relationship of physical activity and diabetes in Pima Indians. Diabetes Care 1990;13:401-411
32. Lee ET, Cowan LD, Welty TK, et al. All-cause mortality and cardiovascular disease mortality in three American Indian populations, aged 45-74 years, 1984-1988. The Strong Heart Study. Am J Epidemiol 1998;147:995-1008
33. Karas MG, Devereux RB, Wiebers DO, et al. Incremental value of biochemical and echocardiographic measures in prediction of ischemic stroke: the Strong Heart Study. Stroke 2012;43: 720-726
34. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High BloodCholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
35. Stone NJ, Robinson JG, Lichtenstein AH, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129(Suppl. 2):S1-S45
36. Zhang Y, Galloway JM, Welty TK, et al. Incidence and risk factors for stroke in American Indians: the Strong Heart Study. Circulation 2008;118:1577-1584
37. Boden WE, Probstfield JL, Anderson T, et al.; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-2267
38. Geiss LS, Wang J, Cheng YJ, et al. Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012. JAMA 2014;312: 1218-1226
39. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001;286:1195-1200
40. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308